In PC, CA19-9 (a carcinoembryonic antigen) is approved by the FDA for prognostic monitoring in patients with known PC; however, it is considered having low sensitivity and specificity for PC detection (Eissa et al., 2019). Here, CEACAM5 is linked to pachyonychia congenita.